Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05552222 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Name: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma — clinical trial record (NCT05552222)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MajesTEC-7

StatusRecruiting

PhasePhase 3

SponsorJanssen Research & Development, LLC

Started2022-10-25

View on ClinicalTrials.gov ↗

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

Amendment history 1 change detected by DataLookout

2026-06-06

Trial sites expanded: 265 → 270 locations

Trial Details

NCT Number	NCT05552222
Lead Sponsor	Janssen Research & Development, LLC
Conditions	Multiple Myeloma
Enrollment	1,590 participants
Start Date	2022-10-25
Primary Completion	2031-04-30 (estimated)
Study Completion	2033-10-28 (estimated)
Updated on ClinicalTrials.gov	2026-08-28